Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × mCRPC × tislelizumab × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

mCRPC 1 Turcot syndrome 1 Pseudomyxoma Peritonei 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Insulin-Like Growth Factor I, Resistance To 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms, Hereditary Nonpolyposis 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07389187 2026-02-05

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Shanghai Changzheng Hospital

Phase EARLY_PHASE1 Not yet recruiting

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡